Advancing TriGlytza, a pancreatic beta-cell centric combination product for treating Type 2 diabetes and Covid
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free